Currently, there are at least 19 Tylenol/acetaminophen Autism and attention deficit hyperactivity disorder (ADHD) lawsuits filed in U.S. District Courts nationwide. All cases raise similar allegations that various manufacturers and distributors of drugs containing acetaminophen—the active ingredient in Tylenol—failed to warn about the risks of Autism and ADHD associated with prenatal exposure to acetaminophen.

Tylenol/acetaminophen Autism lawsuits are being filed across the country with a new class action lawsuit pending certification in federal court. Oral argument before the U.S. Judicial Panel on Multidistrict Litigation on the motion to consolidate the acetaminophen Autism cases into a multidistrict litigation (MDL) class action lawsuit has been set for September 29, 2022, in St. Louis.

N-acetyl-p-aminophenol (APAP), otherwise known as acetaminophen, is an important medication for the treatment of high fever and severe pain, and alternatives are limited. It is available under brand names such as Tylenol, Mapap, and Panadol, and also as generic and store-specific brands. APAP is one of the most commonly used medicines globally. Increasing experimental and epidemiological research suggest that prenatal exposure to APAP might alter fetal development.1

Studies consistently suggest that prenatal APAP exposure might increase the risk of adverse neurodevelopmental and behavioral outcomes, such as ADHD, Autism spectrum disorder (ASD), language delay (in girls), and decreased intelligence quotient.1

Gathering Evidence for a Lawsuit

Evidence for a Tylenol/acetaminophen lawsuit may include:

• Medical records on Tylenol/acetaminophen use during pregnancy (if available)
• Receipts for purchase of acetaminophen
• Medical records indicating that your child was diagnosed with a neurological disorder related to acetaminophen exposure
• Records from your child’s therapist or psychiatrist, if necessary
• Any notes from doctors or healthcare professionals about Tylenol/acetaminophen use during pregnancy


1.       Bauer, AZ., et al. Paracetamol use during pregnancy–a Call for precautionary action. Nat. Rev. Endocrinol. 17, 757–766 (2021)

2.       Bauer, AZ. et al. Prenatal paracetamol exposure and child neurodevelopment: a review. Horm. Behav. 101, 125–147 (2018).

3.       Markets and Research. Global Acetaminophen Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2026. (2020).

4.       Zablotsky, B. et al. Prevalence and trends of developmental disabilities among children in the US: 2009–2017. Pediatrics 144, e20190811 (2019).

5.       Yuelong, JI. et al. Association of cord plasma biomarkers of in utero acetaminophen exposure with risk of attention-deficit/hyperactivity disorder and autism spectrum disorder in childhood. JAMA Psychiatry. 77, 180–189 (2020).

6.       Baker, BH. et al. Association of prenatal acetaminophen exposure measured in meconium with risk of attention-deficit/hyperactivity disorder mediated by frontoparietal network brain connectivity. JAMA Pediatr. 174, 1073–1081 (2020).

7.       About Lawsuits. Extension Granted For Responses to MDL Motion for Acetaminophen Autism, ADHD Lawsuits. Retrieved from (2022).

8.       Yuelong JI, (2020). “Cord Plasma Biomarkers of in Utero Acetaminophen Exposure and ADHD and ASD Risk.” JAMA Psychiatry, JAMA Network. Retrieved from

9.       Miller & Zois, LLC (2022)

10.   Claudia, BAG. et al. Acetaminophen use in pregnancy and neurodevelopment: attention function and autism spectrum symptoms. Int. J. Epidemiol. 45, 6, 1987–1996 (2016)

Leave a Reply

Your email address will not be published. Required fields are marked *